These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23538159)

  • 1. Incidence, predictors and management of left main coronary artery stent restenosis: a comprehensive review in the era of drug-eluting stents.
    De Caterina AR; Cuculi F; Banning AP
    EuroIntervention; 2013 Mar; 8(11):1326-34. PubMed ID: 23538159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unprotected left main coronary artery stenting with zotarolimus (Endeavor) drug-eluting stents: a single center retrospective experience.
    Simard T; Hibbert B; Chong AY; Ruchin P; Le May M; Labinaz M; Froeschl M; So D; Glover C; Marquis JF; O'Brien E
    Catheter Cardiovasc Interv; 2012 Aug; 80(2):E15-22. PubMed ID: 21805580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kissing drug-eluting balloons for the treatment of unprotected distal left main bifurcation drug-eluting stent restenosis.
    Ielasi A; Anzuini A
    Cardiovasc Revasc Med; 2012; 13(6):347-9. PubMed ID: 23000439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents 70 restenotic cases from a cohort of 718 patients: FAILS (Failure in Left Main Study).
    Sheiban I; Sillano D; Biondi-Zoccai G; Chieffo A; Colombo A; Vecchio S; Margheri M; Gunn JP; Raina T; Liistro F; Bolognese L; Lee MS; Tobis J; Moretti C
    J Am Coll Cardiol; 2009 Sep; 54(13):1131-6. PubMed ID: 19761932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and Management of Restenosis After Treatment of Unprotected Left Main Disease With Second-Generation Drug-Eluting Stents (from Failure in Left Main Study With 2nd Generation Stents-Cardiogroup III Study).
    D'Ascenzo F; Chieffo A; Cerrato E; Ugo F; Pavani M; Kawamoto H; di Summa R; Varbella F; Boccuzzi G; Omedè P; Rettegno S; Garbo R; Conrotto F; Montefusco A; Biondi-Zoccai G; D'Amico M; Moretti C; Escaned J; Gaita F; Colombo A
    Am J Cardiol; 2017 Apr; 119(7):978-982. PubMed ID: 28131320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of definite stent thrombosis or in-stent restenosis after drug-eluting stent implantation for treatment of coronary in-stent restenosis: from Western Denmark Heart Registry.
    Jensen JK; Jensen LO; Terkelsen CJ; Lassen JF; Tilsted HH; Hansen KN; Maeng M; Thuesen L; Thayssen P
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):260-5. PubMed ID: 22511512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and efficacy of bioresorbable vascular scaffolds use for the treatment of in-stent restenosis and a bifurcation lesion in a heavily calcified diffusely diseased vessel.
    Naganuma T; Costopoulos C; Latib A; Sato K; Miyazaki T; Colombo A
    JACC Cardiovasc Interv; 2014 May; 7(5):e45-6. PubMed ID: 24746654
    [No Abstract]   [Full Text] [Related]  

  • 9. Repeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year.
    Stolker JM; Cohen DJ; Kennedy KF; Pencina MJ; Lindsey JB; Mauri L; Cutlip DE; Kleiman NS;
    Circ Cardiovasc Interv; 2012 Dec; 5(6):772-82. PubMed ID: 23093553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
    Laynez A; Sardi G; Hauville C; Barbash IM; Pakala R; Torguson R; Xue Z; Satler LF; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):759-65. PubMed ID: 22488756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioresorbable vascular scaffold implantation for recurrent in-stent restenosis: an option in case of multiple failures?
    Ielasi A; Saino A; Silvestro A; Personeni D; Tespili M
    EuroIntervention; 2014 Jul; 10(3):337. PubMed ID: 24647134
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute closure after stenting: not always a thrombus.
    Badr S; Dvir D; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2013 Nov; 82(5):765-7. PubMed ID: 23239619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and procedural predictors of suboptimal outcome after the treatment of drug-eluting stent restenosis in the unprotected distal left main stem: the Milan and New-Tokyo (MITO) registry.
    Takagi K; Ielasi A; Shannon J; Latib A; Godino C; Davidavicius G; Mussardo M; Ferrarello S; Figini F; Carlino M; Montorfano M; Chieffo A; Nakamura S; Colombo A
    Circ Cardiovasc Interv; 2012 Aug; 5(4):491-8. PubMed ID: 22851528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left Main restenosis in the DES era - a call for action.
    di Palma G; Cortese B
    Cardiovasc Revasc Med; 2018 Jun; 19(4):466-470. PubMed ID: 29169984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-hospital and mid-term outcomes of stent implantation in patients with protected and unprotected left main coronary artery disease; King Chulalongkorn Memorial Hospital experiences.
    Cholteesupachai J; Udayachalerm W; Srimahachota S; Buddhari W; Chaipromprasit J; Songmuang SB; Suithichaiyakul T
    J Med Assoc Thai; 2009 Jun; 92(6):755-60. PubMed ID: 19530580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of provisional side-branch T-stenting for the treatment of unprotected distal left main coronary artery disease.
    De Luca L; Altamura L; Corvo P; De Persio G; Ghini AS; Petrolini A; Aurigemma C; Tomai F
    Catheter Cardiovasc Interv; 2011 May; 77(6):765-72. PubMed ID: 21413124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unprotected left main disease managed with drug-eluting stents: long-term outcome of 100 patients with increased surgical risk.
    Wood FO; Saylors EK; Schneider JE; Jobe RL; Mann JT
    Catheter Cardiovasc Interv; 2008 Mar; 71(4):533-8. PubMed ID: 18307224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percutaneous coronary intervention of unprotected left main coronary artery disease: procedural strategies and technical considerations.
    Lee MS; Stone GW; Park SJ; Teirstein P; Moses J; Colombo A; Kandzari DE
    Catheter Cardiovasc Interv; 2012 Apr; 79(5):812-22. PubMed ID: 21793172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New-Generation Drug-Eluting Stents for Left Main In-Stent Restenosis: The DELTA-2 Registry.
    Giustino G; Tanaka A; Erglis A; Morice MC; Van Mieghem NM; Meliga E; D'Ascenzo F; Stefanini GG; Capodanno D; Chieffo A;
    JACC Cardiovasc Interv; 2018 Dec; 11(23):2438-2440. PubMed ID: 30522680
    [No Abstract]   [Full Text] [Related]  

  • 20. Unprotected left main stenting in the real world: five-year outcomes of the French Left Main Taxus registry.
    Mylotte D; Meftout B; Moynagh A; Vaquerizo B; Darremont O; Silvestri M; Louvard Y; Leymarie JL; Morice MC; Lefèvre T; Garot P
    EuroIntervention; 2012 Dec; 8(8):970-81. PubMed ID: 23014945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.